DiaSorin (OTCMKTS:DSRLF) Hits New 12-Month Low - Time to Sell?

Key Points

• DiaSorin S.p.A. hit a new 52-week low, trading as low as $94.25, down from a previous close of $100.00.
• Analysts from Royal Bank Of Canada and Morgan Stanley have upgraded DiaSorin’s stock rating to "outperform" and "overweight", respectively, indicating growing investor confidence.
• The stock has a Moderate Buy average rating among analysts, with two giving it a Buy rating and one a Hold rating.

DiaSorin S.p.A. (OTCMKTS:DSRLF - Get Free Report) hit a new 52-week low on Saturday . The company traded as low as $94.25 and last traded at $94.25, with a volume of 1 shares traded. The stock had previously closed at $100.00.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on DSRLF. Royal Bank Of Canada upgraded DiaSorin to an "outperform" rating in a research note on Thursday, August 14th. Morgan Stanley upgraded DiaSorin from an "underweight" rating to an "overweight" rating in a research note on Tuesday, August 26th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy".

DiaSorin Stock Performance

The firm has a fifty day moving average price of $104.15 and a 200 day moving average price of $106.59.

DiaSorin Company Profile

DiaSorin S.p.A. engages in development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIASON IQ, LIAISON XL, LIAISON XXL, and LIAISON XL LAS.